Awareness screening and referral patterns among pediatricians in the United States related to early clinical features of spinal muscular atrophy (SMA)

Table 5 2018–2019 Comparison of Utilization Frequency of Screening Tools in Clinic

	Each frequency comparison
	2018 Response^a	2019 Response	p value
Tools are administered as concerns appear during developmental surveillance			< 0.0001
Yes	32.7%	8.0%
No	67.3%	92.0%
Tools are administered at 9-, 18-, and 30-month visits			< 0.0001
Yes	41.3%	15.0%
No	58.7%	85.0%
Tools are administered at each well visit			< 0.0001
Yes	56.0%	37.3%
No	44.0%	62.7%
Tools are administered at 9-, 18-, and 30-month visits and as concerns appear during developmental surveillance			< 0.0001
Yes	18.0%	35.7%
No	82.0%	64.3%
Tools are not administered in practice			Option not provided in 2018 Survey
Yes		4.0%
No		96.0%

In 2019, respondents were instructed to select the option that best described the frequency of tool administration within their practice. ^aIn 2018 each pediatrician had the option to ‘select all that apply’ for the following provided responses: Tools are administered as concerns appear during developmental surveillance; Tools are administered at 9-, 18-, and 30-month visits; Tools are administered at each well visit. Respondents that selected both ‘Tools are administered as concerns appear during developmental surveillance’ and ‘Tools are administered at 9-, 18-, and 30-month visits’ were also listed within the row labeled ‘Tools are administered at 9-, 18-, and 30-month visits and as concerns appear during developmental surveillance’

ISSN: 1471-2431